- Trial phase
- Approved
- Time to market
- Already on the market. Minocin for Injection has been FDA-approved since at least 2015 (newer formulation) and was originally approved in the 1970s.
- Why 4/10
- Minocin is already FDA-approved and commercially marketed with no pending regulatory decision or pivotal readout. The next hard catalyst for CorMedix overall is the Rezzayo sNDA PDUFA (Q1 2027), but that is a different drug. Minocin itself has no scheduled binary catalyst in the next 12 months, capping the impact score at 5.
Minocin is already approved and commercialized with no upcoming binary catalyst. The next events for CRMD are Q3 2026 earnings (Nov 12, 2026) and the Rezzayo sNDA PDUFA (Q1 2027), but neither is specific to Minocin. The key thing to watch is whether the Heron Therapeutics asset acquisition (announced Nov 9, 2026) closes as expected in 2027 and how Minocin revenue trends as part of the broader Melinta portfolio.
Price Chart
Executive Summary
Minocin (minocycline for injection) is an FDA-approved intravenous tetracycline antibiotic that CorMedix (CRMD) acquired through its $300M purchase of Melinta Therapeutics in September 2025. It is one of several marketed hospital products in CorMedix's portfolio, alongside DefenCath (the company's primary revenue driver) and Rezzayo. In June 2026, the Federal Circuit upheld CorMedix's Minocin patents and barred Nexus Pharmaceuticals from launching a generic version before patent expiration, protecting the product's market exclusivity. Minocin is already commercialized with no upcoming regulatory catalyst of its own; the stock's next near-term events are Q3 2026 earnings (Nov 12, 2026) and the Rezzayo sNDA PDUFA (Q1 2027).
How It Works
Minocin (minocycline) is a tetracycline-class antibiotic that stops bacterial growth by blocking protein production inside bacteria. It is given intravenously (IV) to treat serious bacterial infections, particularly those caused by susceptible strains where oral antibiotics are not appropriate.
Trial Status
Minocin is an FDA-approved, commercially marketed product. No active clinical trials were found for Minocin specifically under CorMedix. The drug's patent protection was upheld by the Federal Circuit in June 2026.
The Two-Sided Case
Upcoming Catalysts
- Q3 2026 earnings report (Nov 12, 2026, before market open)
- Heron Therapeutics asset acquisition closing (expected 2027)
- Rezzayo sNDA PDUFA for prophylaxis of invasive fungal diseases (Q1 2027)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
CorMedix Inc. 8-K CRMD ·Originating report